Related references
Note: Only part of the references are listed.Efficacy and safety of denileukin diftitox (Dd) in cutaneous T-cell lymphoma (CTCL) patients: Integrated analysis of three large phase III trials
A. Negro-Vilar et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Clinical Studies of Histone Deacetylase Inhibitors
H. Miles Prince et al.
CLINICAL CANCER RESEARCH (2009)
Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sezary syndrome
Gaelle Quereux et al.
ARCHIVES OF DERMATOLOGY (2008)
Long-term experience with low-dose interferon-α and PUVA in the management of early mycosis fungoides
S Rupoli et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2005)
Hazard ratio in clinical trials
SL Spruance et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma
U Wollina et al.
CANCER (2003)
Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome - Clinical prognostic factors and risk for disease progression
YH Kim et al.
ARCHIVES OF DERMATOLOGY (2003)
Topical nitrogen mustard in the management of mycosis fungoides - Update of the Stanford experience
YH Kim et al.
ARCHIVES OF DERMATOLOGY (2003)
Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas - The severity-weighted assessment tool (SWAT)
SR Stevens et al.
ARCHIVES OF DERMATOLOGY (2002)
Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational phase II-III trial results
M Duvic et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma
E Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
